Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 6:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Drug Discontinuation Clear all
Completed No phase listed Observational Results available

Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study

NCT04754542
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
55 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Aurora, Colorado • Kansas City, Kansas • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Jun 25, 2026, 6:41 PM EDT
Terminated No phase listed Observational

End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia

NCT01386723
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Discontinuation of eltrombopag
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Jun 25, 2026, 6:41 PM EDT
Recruiting Phase 2 Interventional

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

NCT06511882
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Decitabine, Venetoclax
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

NCT00005001
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 Immunogen
Biological
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
13 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 25, 2026, 6:41 PM EDT
Completed No phase listed Observational

Identifying Factors Underlying the Discontinuation of Triptans

NCT00890357
View directory record Official record
Conditions
Migraine, Medication Adherence
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Tampa, Florida • St Louis, Missouri • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Jun 25, 2026, 6:41 PM EDT
Completed No phase listed Observational

A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely

NCT05202301
View directory record Official record
Conditions
Prostate Cancer
Interventions
Darolutamide (Nubeqa, BAY1841788), Enzalutamide, Apalutamide
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
13,779 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Jun 25, 2026, 6:41 PM EDT
Withdrawn Phase 1 Interventional

A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects

NCT06711640
View directory record Official record
Conditions
Opioid Withdrawal (Disorder), Opioid Use Disorder
Interventions
LUCEMYRA (lofexidine) tablets
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
12 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban

NCT01826266
View directory record Official record
Conditions
Anticoagulant Reversal, Reversal of Edoxaban Induced Anticoagulation
Interventions
PER977, Placebo
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of the Effects of MDMA/Ecstasy on Water Regulation, Sleep, and Cognition.

NCT01053403
View directory record Official record
Conditions
MDMA Discontinuation Syndrome
Interventions
3,4-methylenedioxymethamphetamine or Placebo
Drug
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Jun 25, 2026, 6:41 PM EDT
Not yet recruiting Not applicable Interventional

Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation

NCT07387796
View directory record Official record
Conditions
Drug Discontinuation, Substance Use Disorders, Eating Behavior Changes, Tirzepatide
Interventions
Discontinuation and Reinitiation of Tirzepatide
Other
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 25, 2026, 6:41 PM EDT
Not yet recruiting Not applicable Interventional

Scalable Behavioral Program for Weight Loss Maintenance After GLP-1 and Anti-Obesity Medication Discontinuation

NCT07535892
View directory record Official record
Conditions
Weight Loss, GLP - 1, Weight Loss Maintenance, Obesity & Overweight
Interventions
Weight Loss Maintenance Program (Foundational), Mom's Meals, YMCA Membership, SKY Meditation Program
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jun 25, 2026, 6:41 PM EDT
Terminated Phase 4 Interventional Results available

Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain

NCT02741076
View directory record Official record
Conditions
Opioid-Related Disorders, Opiate Addiction, Narcotic Abuse, Drug Abuse
Interventions
Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER), Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
Drug
Lead sponsor
Member Companies of the Opioid PMR Consortium
Industry
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
61
States / cities
Foley, Alabama • Mobile, Alabama • Montgomery, Alabama + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Jun 25, 2026, 6:41 PM EDT
Not yet recruiting No phase listed Observational

Real-World Evaluation of Compl-AI for Predicting Early Medication Dropout in Opioid Use Disorder Treatment

NCT07456930
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Not listed
Lead sponsor
Tools4Patient
Other
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
San Diego, California • Vista, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Phase 4 Interventional Results available

The Effects of ADHD Medication (TEAM) Study

NCT02293655
View directory record Official record
Conditions
ADHD
Interventions
OROS-Methylphenidate (MPH)
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 11 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Cincinnati, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Not applicable Interventional Results available

Statin Discontinuation in Advanced Illness

NCT01415934
View directory record Official record
Conditions
Palliative Medicine, Cardiovascular Disease
Interventions
discontinue statins
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Not applicable Interventional

A Study on the Rate of Opportunistic (AIDS-Related) Infections Among HIV-Positive Children Who Have Stopped Taking Their OI Preventive Medications

NCT00001078
View directory record Official record
Conditions
HIV Infections
Interventions
Hepatitis A Vaccine (Inactivated)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 21 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Jun 25, 2026, 6:41 PM EDT
Recruiting Phase 4 Interventional

Enhancing Hypnotic Medication Discontinuation in Primary Care

NCT06435520
View directory record Official record
Conditions
Insomnia, Hypnotic Dependence
Interventions
Digital Cognitive Behavioral Therapy, Structured Medication Tapering
Behavioral
Lead sponsor
National Jewish Health
Other
Eligibility
21 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jun 25, 2026, 6:41 PM EDT
Completed No phase listed Observational

Withdrawal of Antifungal Treatment for Histoplasmosis in Patients After Improved Immune Response to Anti-HIV Drugs

NCT00006316
View directory record Official record
Conditions
HIV Infections, Histoplasmosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2008 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Not applicable Interventional Results available

Discontinuation From Chronic Opioid Therapy For Pain Using a Buprenorphine Taper

NCT02737826
View directory record Official record
Conditions
Chronic Pain, Opioid Pain Medication
Interventions
Buprenorphine Initiation - Phase I, Gabapentin + Buprenorphine - Phase II, Placebo + Buprenorphine - Phase II, Buprenorphine taper - Phase II
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Not applicable Interventional

Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients

NCT00001131
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin, HAART
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Jun 25, 2026, 6:41 PM EDT
Completed No phase listed Observational

Effects of Therapeutic HIV Vaccination on Control of HIV After Discontinuation of Anti-HIV Drugs

NCT00050063
View directory record Official record
Conditions
HIV Infections
Interventions
Therapeutic vaccinations from A5058s
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
14
States / cities
Torrance, California • Aurora, Colorado • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Phase 2 Interventional Results available

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

NCT00378482
View directory record Official record
Conditions
Colorectal Neoplasms, Melanoma, Prostatic Neoplasms, Renal Cell Carcinoma, Neoplasms, Patients Who Have/Have Had Melanoma and Other Tumors
Interventions
CP-675,206 (Tremelimumab)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
5
States / cities
Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Jun 25, 2026, 6:41 PM EDT
Recruiting Phase 3 Interventional

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

NCT06377852
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Palbociclib 125mg, Ribociclib 600mg, Ribociclib, Palbociclib
Drug
Lead sponsor
American Society of Clinical Oncology
Other
Eligibility
65 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
73
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Phase 4 Interventional Results available

Facilitation of Zolpidem (≥10 mg) Discontinuation Through Use of Ramelteon in Subjects With Chronic Insomnia

NCT00492232
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Ramelteon and zolpidem, Placebo and zolpidem
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
41
States / cities
Hot Springs, Arkansas • Anaheim, California • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2010 · Synced Jun 25, 2026, 6:41 PM EDT